跳至主要内容
临床试验/ISRCTN12273637
ISRCTN12273637已完成不适用

Targeting on the values of Wolbachia endosymbionts as novel feasible anti-filarial chemotherapeutic approach to prevent/reduce/clear disease in lymphatic filariasis and interrupt transmission in endemic communities of Tanzania: a randomised double-blind placebo-controlled trial

Volkswagen Foundation (VolkswagenStiftung) (Germany)0 个研究点目标入组 90 人开始时间: 2009年3月5日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Age range 18 - 68 years
  • 2. Males and females
  • 3. Diagnosed clinically to have lymphoedema stages I - V
  • 4. Permanent residents in the study area
  • 5. May be microfilaraemia positive or negative

排除标准

  • 1. Children and pregnant women
  • 2. Chronic liver, kidney, cardiac, central nervous system disease
  • 3. Allergy to the trial drugs
  • 4. Previous history of using anti-filarial drugs, e.g. ivermectin, albendazole, diethylcarbamazine
  • 5. Past history of taking anti-geohelminthics, e.g. mebendazole, and antibiotics such as tetracycline or rifampicin in the last six months

研究者

发起方
Volkswagen Foundation (VolkswagenStiftung) (Germany)

相似试验